The Hippocratic Post Cites The Regenerative Clinic in Significant Discovery for the Management of Osteoarthritis

The Hippocratic Post Cites The Regenerative Clinic in Significant Discovery for the Management of Osteoarthritis

In a new article published by The Hippocratic Post, they have cited The Regenerative Clinic in reference to a new study on the improvement of patients suffering with osteoarthritis. Taken from the pages of the article, they write:

60% of osteoarthritis sufferers see improvement: First of a kind study evidences effectiveness of MFAT on pain and improved joint function 2 years after treatment.

In a significant discovery for the management of osteoarthritis, a team of surgeons led by experts in London has found that 60% hip osteoarthritis patients experienced an improvement in pain over a 2-year period as a result of micro-fragmented adipose tissue (MFAT) injections.

The study is the largest of its type to be recorded and measures the effectiveness of micro-fragmented adipose tissue (MFAT) injections, and separately the combination treatment of MFAT with platelet-rich plasma (PRP).

The research is a joint project between experts at The Regenerative Clinic, London, The George Emil Palade University, Romania, Manchester Metropolitan University, Manchester and University of Ferrara, Italy. 147 patients suffering from grade 1–4 hip osteoarthritis took part in the study. Hip osteoarthritis (OA) is a major contributor to reduced quality of life and concomitant disability associated with lost working life months.

The peer reviewed research has been published in The Journal of Clinical Medicine in February 2022 and is available as a downloadable pdf. Key findings are:

  • Over 60% patients report an improvement in pain
  • This is using both visual analogue score for pain (VAS) and Oxford hip score (OHS)
  • It shows that an intra-articular injection of MFAT + PRP suggest a positive role for patients with a lower BMI where there may be difficulty in obtaining sufficient MFAT
  • In each of the MFAT and MFAT + PRP groups, only 10 patients went on to have a total hip replacement as they did not respond to the treatment. Of these 20, most had higher grades of osteoarthritis (KL 3 and 4)
  • No infections or thromboembolic events were observed
  • In this first of its kind clinical study, researchers have shown the efficacy of MFAT and combinational preparation in successful amelioration of hip pain together with improved joint function in patients treated with osteoarthritis
  • A larger clinical trial is warranted to determine long-term benefits over 2–5 years, and any gender-related differences in response

Professor Nima Heidari, Consultant Orthopaedic and Trauma Surgeon, said; “In this first of its kind clinical study, we have shown the efficacy of MFAT and combinational preparation in successful amelioration of hip pain together with improved joint function in patients treated with osteoarthritis. Both types of intra-articular injections were equally effective in improving pain scores over 6–12 months. We look forward to a larger clinical trial characterize in detail the effectiveness in patients with different grades of osteoarthritis, to determine long-term benefits over 2–5 years, and any osteoarthritis gender-related differences in response.”

He continues; “This work has provided an insight into the optimal time period for MFAT treatments to be effective. Some participants went on to have hip replacement because the hip had deteriorated too far before MFAT treatment commenced. When hip osteoarthritis is very advanced, and the femoral head loses its natural spherical shape then it is unlikely that these kinds of treatments can provide long term effective pain relief.”

If you’re interested in getting treatment or seeing on of our renowned specialists, then leave an enquiry below now!

You can read the full article on The Hippocratic Post here

 

 

Leave a Reply

Your email address will not be published.

Get in touch

Find your clinic

We offer appointments nationwide and now working with partners abroad providing cutting edge Regenerative Medicine to patients in Dubai, Australia, Spain and Pakistan.